Ceftobiprole combines an excellent spectrum for community-acquired
pneumonia (CAP) and
hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-
lactams' safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events by anti-MRSA coverage as
oxazolidinones or
glycopeptides. We aimed to report the available evidence regarding
ceftobiprole use in
pneumonia and invasive
bacterial infections, shedding light on
ceftobiprole stewardship. The clinical application and real-life experiences of using
ceftobiprole for
bloodstream infections, including
infective endocarditis, are limited but nevertheless promising. In addition, extended-spectrum
ceftobiprole activity, including Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa, has theoretical advantages for use as empirical
therapy in
bacteremia potentially caused by a broad spectrum of microorganisms, such as
catheter-related
bacteremia. In the future, the desirable approach to
sepsis and severe
infections will be administered to patients according to their clinical situation, the intrinsic host characteristics, the susceptibility profile, and local epidemiology, while the "universal
antibiotic strategy" will no longer be adequate.